Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06543576 · ClinicalTrials.gov registry record · Phase 1
External Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cervical Cancer
A Phase 1 study of Cervical Squamous Cell Carcinoma and Cervical Adenocarcinoma, sponsored by Jonsson Comprehensive Cancer Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
- 4
- Study locations
NCT06543576 is a Phase 1 study of Cervical Squamous Cell Carcinoma and Cervical Adenocarcinoma that is actively recruiting participants, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 35 participants, below the 120-participant average among 13 other Cervical Squamous Cell Carcinoma trials with a reported enrollment target (71% lower). The trial reports 4 study locations across 3 states.
The verdict
NCT06543576, a Phase 1 study of Cervical Squamous Cell Carcinoma and Cervical Adenocarcinoma, is actively recruiting participants, sponsored by Jonsson Comprehensive Cancer Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
- 4
- Study locations
Study Summary
This phase I/II trial tests the safety and effectiveness of receiving external beam radiation therapy (EBRT) and brachytherapy along with chemotherapy, consisting of cisplatin and paclitaxel, and immunotherapy, consisting of bevacizumab and pembrolizumab, for the treatment of patients with stage IVB cervical cancer. EBRT is type of radiation therapy that uses a machine to aim high-energy rays at the cancer from outside of the body. Brachytherapy, also known as internal radiation therapy, uses radioactive material placed directly into or near a tumor to kill tumor cells. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Paclitaxel is in a class of medications called antimicrotubule agents. It stops tumor cells from growing and dividing and may kill them. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. A monoclonal antibody, such as pembrolizumab, is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Giving EBRT and brachytherapy along with chemotherapy and immunotherapy may be a safe and effective way to treat patients with stage IVB cervical cancer.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- DRUG Cisplatin
- RADIATION External Beam Radiation Therapy
- RADIATION Brachytherapy
- BIOLOGICAL Bevacizumab
Study Locations (4)
California
- UCLA / Jonsson Comprehensive Cancer Center - Los Angeles
- University of California San Diego (UCSD) - San Diego
Oklahoma
- University of Oklahoma Health Sciences Center - Oklahoma City
Virginia
- University of Virginia Cancer Center - Charlottesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2025-07-29 |
| Est. Completion | 2032-01-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06543576
The ClinicalTrials.gov registry entry for NCT06543576 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 120-participant average among 13 other Cervical Squamous Cell Carcinoma trials with a reported enrollment target (71% lower). The listed sponsor is Jonsson Comprehensive Cancer Center, which has 321 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Cervical Squamous Cell Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT06543576 reports 4 study locations spanning 3 distinct geographic areas - top geographies include California, Oklahoma, Virginia.
Frequently Asked Questions
What is clinical trial NCT06543576 about?
NCT06543576 is a clinical study titled "External Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cervical Cancer". This phase I/II trial tests the safety and effectiveness of receiving external beam radiation therapy (EBRT) and brachytherapy along with chemotherapy, consisting of cisplatin and paclitaxel, and immunotherapy, consisting of bevacizumab and pembrolizumab, for the treatment of patients with stage IVB...
What is the current status of trial NCT06543576?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2025-07-29. Estimated completion is 2032-01-31.
What conditions does trial NCT06543576 study?
This clinical trial studies the following conditions: Cervical Squamous Cell Carcinoma, Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Stage IVB Cervical Cancer American Joint Committee on Cancer (AJCC) v8.
What interventions are being tested in trial NCT06543576?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Cisplatin (DRUG), External Beam Radiation Therapy (RADIATION), Brachytherapy (RADIATION), Bevacizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT06543576?
This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06543576 being conducted?
This trial has 4 study locations across California, Oklahoma, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cervical Squamous Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
RECRUITING · Phase 1
-
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
RECRUITING · Phase 1
-
A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors
RECRUITING · Phase 1
-
Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications
ACTIVE NOT RECRUITING · Phase 1
-
Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer
COMPLETED · Phase 1
-
Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers
ACTIVE NOT RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.